Clinical Trials at Massachusetts General Hospital

As of July 2026, 599 paid clinical trials are recruiting at Massachusetts General Hospital, located at Faustman Lab at Massachusetts General Hospital, 149 13th St #3602, Boston, MA 02129, phone (617) 726-4084 in Boston, Massachusetts. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

604 clinical trials at Massachusetts General Hospital

·Clear filters·↓ Download CSV

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

for Recurrent Pericarditis

21 locations incl. Phoenix

Sponsor: Cardiol Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06708299·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

for Recurrent Ovarian Cancer

Drug: Cemiplimab

11 locations incl. Birmingham

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18+

Code: NCT03564340·Phase 1, Phase 2·Recruiting·Listed Jun 2018

Apply to this trial

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

for ANCA Associated Vasculitis (AAV)

11 locations incl. Aurora

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 75

Code: NCT06868290·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

for Systemic Lupus Erythematosus

21 locations incl. Orange

Sponsor: Cabaletta Bio

Sex: All·Age: 18 - 65

Code: NCT06121297·Phase 1, Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Drug: Soquelitinib

21 locations incl. Duarte

Sponsor: Corvus Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06561048·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

for Acute Myeloid Leukemia

Drug: Venetoclax

24 locations incl. Los Angeles

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06456463·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

for Solid Tumors

18 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT05203172·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

for Melanoma Stage IV

11 locations incl. Scottsdale

Sponsor: Georgiamune Inc

Sex: All·Age: 18+

Code: NCT06425926·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for Advanced or Metastatic Solid Tumors

14 locations incl. Phoenix

Sponsor: 858 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06395519·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

for Venous Leg Ulcer (VLU)

14 locations incl. Fresno

Sponsor: MediWound Ltd

Sex: All·Age: 18+

Code: NCT06568627·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

for Ovarian Cancer

14 locations incl. Augusta

Sponsor: Compugen Ltd

Sex: Female·Age: 18+

Code: NCT06888921·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

for Locally Advanced Solid Tumor

17 locations incl. Irvine

Sponsor: Nuvalent Inc.

Sex: All·Age: 18+

Code: NCT06521554·Phase 1·Recruiting·Listed Jul 2024

Apply to this trial

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

for Myasthenia Gravis

17 locations incl. San Francisco

Sponsor: argenx

Sex: All·Age: 18+

Code: NCT06298565·Recruiting·Listed Mar 2024

Apply to this trial

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

for Non Small Cell Lung Cancer

24 locations incl. Beverly Hills

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT05983432·Phase 1·Recruiting·Listed Aug 2023

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

24 locations incl. Tucson

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

Medtronic Terminate AF Study

for Persistent Atrial Fibrillation

15 locations incl. Indianapolis

Sponsor: Medtronic Cardiac Surgery

Sex: All·Age: 18+

Code: NCT03546374·Recruiting·Listed Jun 2018

Apply to this trial

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

for EPP

15 locations incl. Huntington Beach

Sponsor: Tanabe Pharma America, Inc.

Sex: All·Age: 12 - 75

Code: NCT05005975·Phase 3·Recruiting·Listed Aug 2021

Apply to this trial

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

for Locally Advanced Solid Tumor

15 locations incl. Palo Alto

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05732831·Phase 1, Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

CERAMENT™| Bone Void Filler Device Registry

for Orthopedic Disorder

13 locations incl. Scottsdale

Sponsor: BONESUPPORT AB

Sex: All·Age: 18+

Code: NCT04244942·Recruiting·Listed Jan 2020

Apply to this trial

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

for Ovarian Cancer

Drug: Cemiplimab

13 locations incl. Duarte

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18+

Code: NCT04590326·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

MB-105 in Patients With CD5 Positive T-cell Lymphoma

for Lymphoma, T-Cell

12 locations incl. San Diego

Sponsor: March Biosciences Inc

Sex: All·Age: 18+

Code: NCT06534060·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for Solid Tumor, Adult

13 locations incl. Los Angeles

Sponsor: GV20 Therapeutics

Sex: All·Age: 18+

Code: NCT05669430·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Pilot/Pivotal Study of DBS+Rehab After Stroke

for Stroke

10 locations incl. Phoenix

Sponsor: Enspire DBS Therapy, Inc.

Sex: All·Age: 21+

Code: NCT05701280·Recruiting·Listed Jan 2023

Apply to this trial

A Retrospective Assessment of OviTex PRS (OviTex)

for Reconstructive Surgical Procedures

11 locations incl. Naples

Sponsor: Tela Bio Inc

Sex: Female·Age: 18 - 75

Code: NCT05736848·Recruiting·Listed Feb 2023

Apply to this trial

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

for Advanced NRAS-Mutant Melanoma

9 locations incl. Los Angeles

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07584226·Phase 1·Recruiting·Listed May 2026

Apply to this trial

Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)

for Erythropoietic Protoporphyria (EPP)

5 locations incl. Boston

Sponsor: Portal Therapeutics, Inc.

Sex: All·Age: 12+

Code: NCT07567131·Recruiting·Listed May 2026

Apply to this trial

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

for ALK-positive NSCLC

11 locations incl. San Francisco

Sponsor: TRIANA Biomedicines, Inc.

Sex: All·Age: 18+

Code: NCT07491497·Phase 1, Phase 2·Recruiting·Listed Mar 2026

Apply to this trial

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

for Bipolar I Disorder

1 location in Boston

Sponsor: Alzamend Neuro, Inc.

Sex: All·Age: 18 - 65

Code: NCT07540338·Phase 1, Phase 2·Recruiting·Listed Apr 2026

Apply to this trial

Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections

for Colorectal Anastomosis

9 locations incl. New Haven

Sponsor: Medtronic - MITG

Sex: All·Age: 18+

Code: NCT07351071·Recruiting·Listed Jan 2026

Apply to this trial

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

for FGFR2 Gene Fusion/Rearrangement

Drug: Lirafugratinib

7 locations incl. Phoenix

Sponsor: Elevar Therapeutics

Sex: All·Age: 18+

Code: NCT07359820·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

for EGFR Mutation Positive Non-small Cell Lung Cancer

Drug: Osimertinib

6 locations incl. Calverton

Sponsor: Nuvectis Pharma, Inc.

Sex: All·Age: 18+

Code: NCT07315113·Phase 1·Recruiting·Listed Jan 2026

Apply to this trial

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

for Amyotrophic Lateral Sclerosis

3 locations incl. Sacramento

Sponsor: Paradromics

Sex: All·Age: 22 - 75

Code: NCT07357428·Recruiting·Listed Jan 2026

Apply to this trial

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

for Platinum-resistant Ovarian Cancer

7 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: Female·Age: 18+

Code: NCT07226427·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

Computer Guided Microwave Liver Ablation

for Hepatocellular Carcinoma (HCC)

2 locations incl. Boston

Sponsor: NE Scientific INC

Sex: All·Age: 18 - 90

Code: NCT07226869·Recruiting·Listed Nov 2025

Apply to this trial

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

for Invasive Mould Infection

6 locations incl. Birmingham

Sponsor: Elion Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07215273·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

First-in-human Study of 7MW4911 in GI Cancer

for GI Cancers

5 locations incl. Port Saint Lucie

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Sex: All·Age: 18+

Code: NCT07216560·Phase 1, Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

for Hormone Receptor-positive Breast Cancer

7 locations incl. Tampa

Sponsor: Ellipses Pharma

Sex: Female·Age: 18+

Code: NCT05573126·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

for Pancreatic Ductal Adenocarcinoma

3 locations incl. Boston

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07024615·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

for Advanced Solid Tumor

5 locations incl. Rogers

Sponsor: Adcendo ApS

Sex: All·Age: 18+

Code: NCT06597721·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

for Vanishing White Matter Disease

3 locations incl. Boston

Sponsor: Calico Life Sciences LLC

Sex: All·Age: 6 Months+

Code: NCT05757141·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial